This Oxervate market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to factors such as the increasing prevalence of diabetes, growing healthcare investment in rare diseases, a rising number of trained ophthalmologists, greater public awareness about eye health and specific conditions, and enhanced patient education programs.
The anticipated growth in the forecast period can be attributed to the development of targeted therapies, a shift towards patient-centric healthcare models, a focus on preventive healthcare, growing awareness of dry eye disease, and the expansion of specialized treatment centers. Key trends expected during the forecast period include advances in gene therapy and regenerative medicine, the use of AI and machine learning in drug development and diagnosis, the rise of telemedicine and remote care, innovations in biotechnology, and advancements in ocular drug delivery systems.
The increasing prevalence of eye inflammation disorders is expected to drive the growth of the oxervate market in the future. Eye inflammation disorders occur when the eye tissues become swollen and irritated, often leading to pain, redness, and vision issues. The rise in these disorders can be attributed to factors such as environmental pollution, increased screen time, allergies, and an aging population. Oxervate helps treat eye inflammation by providing a recombinant form of nerve growth factor (NGF), which promotes the healing of corneal tissue, reduces inflammation, and enhances nerve function, thus restoring the eye's protective barrier. For example, in May 2024, the UK’s GOV.UK reported that in the financial year ending 2023, England recorded over 8.9 million outpatient visits for vision-related issues, equating to a rate of 15,362 per 100,000 population, showing an increase from the previous year. Therefore, the growing incidence of eye inflammation disorders is contributing to the expansion of the oxervate market.
The growing geriatric population is expected to further accelerate the growth of the oxervate market. The geriatric population, consisting of individuals aged 65 and above, often faces age-related health challenges. The increase in this population is due to advancements in healthcare, improved living conditions, and better access to medical treatments. Oxervate offers significant benefits to the elderly by enhancing corneal nerve regeneration and reducing the risk of corneal damage, particularly in individuals with neurotrophic keratitis, a condition common among older adults due to age-related changes in the nervous system. For instance, in July 2024, the UK Parliament’s House of Commons Library reported that in 2022, 12.7 million people in the UK were aged 65 or older, accounting for 19% of the population. This figure is projected to increase to 22.1 million by 2072, making up 27% of the UK population. Therefore, the rising geriatric population is driving the growth of the oxervate market.
The increasing adoption of personalized medicine is expected to further boost the growth of the oxervate market. Personalized medicine involves creating treatment plans based on an individual's unique biological traits, daily habits, and environmental factors, aiming to improve treatment effectiveness and patient outcomes. The growing use of personalized medicine is driven by advancements in genomics, greater access to patient-specific data, and the development of targeted therapies. Oxervate aligns with personalized medicine by focusing on specific biomarkers and tailoring treatment plans, particularly for rare eye conditions such as neurotrophic keratitis, thereby improving treatment outcomes based on each patient’s individual condition and response. For instance, in February 2024, the Personalized Medicine Coalition (PMC) reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, up from six in 2022. As a result, the increasing adoption of personalized medicine is fueling the growth of the oxervate market.
The key company operating in the oxervate market is Dompé Farmaceutici S.p.A.
North America was the largest region in the oxervate market in 2024. The regions covered in oxervate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oxervate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Oxervate (cenegermin-bkbj) is a prescription ophthalmic solution used to treat neurotrophic keratitis, a rare degenerative condition affecting the cornea. It contains cenegermin, a recombinant human nerve growth factor (rhNGF), which aids in the repair and regeneration of corneal tissue by promoting the survival and growth of corneal nerves.
The primary clinical indications for oxervate are neurotrophic keratitis and dry eye disease (DED). Neurotrophic keratitis is a rare, progressive corneal disorder caused by nerve damage, leading to impaired healing, chronic dryness, and potential ulceration. Oxervate is distributed through various channels such as retail pharmacies and online pharmacies, and is used by multiple end users, including hospitals, ophthalmology clinics, and home care providers.
The oxervate market research report is one of a series of new reports that provides oxervate market statistics, including the oxervate industry global market size, regional shares, competitors with the oxervate market share, detailed oxervate market segments, market trends, and opportunities, and any further data you may need to thrive in the oxervate industry. This oxervate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The oxervate market consists of sales of eye drops. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to factors such as the increasing prevalence of diabetes, growing healthcare investment in rare diseases, a rising number of trained ophthalmologists, greater public awareness about eye health and specific conditions, and enhanced patient education programs.
The anticipated growth in the forecast period can be attributed to the development of targeted therapies, a shift towards patient-centric healthcare models, a focus on preventive healthcare, growing awareness of dry eye disease, and the expansion of specialized treatment centers. Key trends expected during the forecast period include advances in gene therapy and regenerative medicine, the use of AI and machine learning in drug development and diagnosis, the rise of telemedicine and remote care, innovations in biotechnology, and advancements in ocular drug delivery systems.
The increasing prevalence of eye inflammation disorders is expected to drive the growth of the oxervate market in the future. Eye inflammation disorders occur when the eye tissues become swollen and irritated, often leading to pain, redness, and vision issues. The rise in these disorders can be attributed to factors such as environmental pollution, increased screen time, allergies, and an aging population. Oxervate helps treat eye inflammation by providing a recombinant form of nerve growth factor (NGF), which promotes the healing of corneal tissue, reduces inflammation, and enhances nerve function, thus restoring the eye's protective barrier. For example, in May 2024, the UK’s GOV.UK reported that in the financial year ending 2023, England recorded over 8.9 million outpatient visits for vision-related issues, equating to a rate of 15,362 per 100,000 population, showing an increase from the previous year. Therefore, the growing incidence of eye inflammation disorders is contributing to the expansion of the oxervate market.
The growing geriatric population is expected to further accelerate the growth of the oxervate market. The geriatric population, consisting of individuals aged 65 and above, often faces age-related health challenges. The increase in this population is due to advancements in healthcare, improved living conditions, and better access to medical treatments. Oxervate offers significant benefits to the elderly by enhancing corneal nerve regeneration and reducing the risk of corneal damage, particularly in individuals with neurotrophic keratitis, a condition common among older adults due to age-related changes in the nervous system. For instance, in July 2024, the UK Parliament’s House of Commons Library reported that in 2022, 12.7 million people in the UK were aged 65 or older, accounting for 19% of the population. This figure is projected to increase to 22.1 million by 2072, making up 27% of the UK population. Therefore, the rising geriatric population is driving the growth of the oxervate market.
The increasing adoption of personalized medicine is expected to further boost the growth of the oxervate market. Personalized medicine involves creating treatment plans based on an individual's unique biological traits, daily habits, and environmental factors, aiming to improve treatment effectiveness and patient outcomes. The growing use of personalized medicine is driven by advancements in genomics, greater access to patient-specific data, and the development of targeted therapies. Oxervate aligns with personalized medicine by focusing on specific biomarkers and tailoring treatment plans, particularly for rare eye conditions such as neurotrophic keratitis, thereby improving treatment outcomes based on each patient’s individual condition and response. For instance, in February 2024, the Personalized Medicine Coalition (PMC) reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, up from six in 2022. As a result, the increasing adoption of personalized medicine is fueling the growth of the oxervate market.
The key company operating in the oxervate market is Dompé Farmaceutici S.p.A.
North America was the largest region in the oxervate market in 2024. The regions covered in oxervate report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the oxervate market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Oxervate (cenegermin-bkbj) is a prescription ophthalmic solution used to treat neurotrophic keratitis, a rare degenerative condition affecting the cornea. It contains cenegermin, a recombinant human nerve growth factor (rhNGF), which aids in the repair and regeneration of corneal tissue by promoting the survival and growth of corneal nerves.
The primary clinical indications for oxervate are neurotrophic keratitis and dry eye disease (DED). Neurotrophic keratitis is a rare, progressive corneal disorder caused by nerve damage, leading to impaired healing, chronic dryness, and potential ulceration. Oxervate is distributed through various channels such as retail pharmacies and online pharmacies, and is used by multiple end users, including hospitals, ophthalmology clinics, and home care providers.
The oxervate market research report is one of a series of new reports that provides oxervate market statistics, including the oxervate industry global market size, regional shares, competitors with the oxervate market share, detailed oxervate market segments, market trends, and opportunities, and any further data you may need to thrive in the oxervate industry. This oxervate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The oxervate market consists of sales of eye drops. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Oxervate Market Characteristics4. Oxervate Market Trends and Strategies5. Oxervate Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Oxervate Pricing Analysis & Forecasts30. Global Oxervate Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Oxervate Market32. Recent Developments in the Oxervate Market
3. Oxervate Market Biologic Drug Characteristics
6. Global Oxervate Growth Analysis and Strategic Analysis Framework
8. Oxervate Market Segmentation
9. Global Oxervate Epidemiology of Clinical Indications
10. Oxervate Market Regional and Country Analysis
11. Asia-Pacific Oxervate Market
12. China Oxervate Market
13. India Oxervate Market
14. Japan Oxervate Market
15. Australia Oxervate Market
16. South Korea Oxervate Market
17. Western Europe Oxervate Market
18. UK Oxervate Market
19. Germany Oxervate Market
20. France Oxervate Market
21. Eastern Europe Oxervate Market
22. North America Oxervate Market
23. USA Oxervate Market
24. Canada Oxervate Market
25. South America Oxervate Market
26. Middle East Oxervate Market
27. Africa Oxervate Market
28. Oxervate Market Competitive Landscape and Company Profiles
29. Global Oxervate Market Pipeline Analysis
33. Oxervate Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Oxervate Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on oxervate market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for oxervate? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The oxervate market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Clinical Indication: Neurotrophic Keratitis; Dry Eye Disease (DED)2) by Distribution Channel: Retail Pharmacies; Online Pharmacies
3) by End User: Hospitals; Ophthalmology Clinics; Home Care
Key Companies Mentioned:Dompé Farmaceutici S.p.a.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Dompé Farmaceutici S.p.A.
